690 related articles for article (PubMed ID: 30411378)
1. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.
Peng YP; Xi CH; Zhu Y; Yin LD; Wei JS; Zhang JJ; Liu XC; Guo S; Fu Y; Miao Y
Oncotarget; 2016 Oct; 7(41):66586-66594. PubMed ID: 27626490
[TBL] [Abstract][Full Text] [Related]
3. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
Chan CJ; Martinet L; Gilfillan S; Souza-Fonseca-Guimaraes F; Chow MT; Town L; Ritchie DS; Colonna M; Andrews DM; Smyth MJ
Nat Immunol; 2014 May; 15(5):431-8. PubMed ID: 24658051
[TBL] [Abstract][Full Text] [Related]
4. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions.
Wu Y; Kuang DM; Pan WD; Wan YL; Lao XM; Wang D; Li XF; Zheng L
Hepatology; 2013 Mar; 57(3):1107-16. PubMed ID: 23225218
[TBL] [Abstract][Full Text] [Related]
5. Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals.
Yin X; Liu T; Wang Z; Ma M; Lei J; Zhang Z; Fu S; Fu Y; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
Front Immunol; 2018; 9():2341. PubMed ID: 30364127
[TBL] [Abstract][Full Text] [Related]
6. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma.
Ren C; Ren X; Cao D; Zhao H; Zhai Z; Li H; Li Y; Fu X; He J; Zhao H
FEBS Open Bio; 2020 May; 10(5):847-860. PubMed ID: 32160402
[TBL] [Abstract][Full Text] [Related]
7. Coming of Age: CD96 Emerges as Modulator of Immune Responses.
Georgiev H; Ravens I; Papadogianni G; Bernhardt G
Front Immunol; 2018; 9():1072. PubMed ID: 29868026
[TBL] [Abstract][Full Text] [Related]
8. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
9. Interaction between nectin-1 and the human natural killer cell receptor CD96.
Holmes VM; Maluquer de Motes C; Richards PT; Roldan J; Bhargava AK; Orange JS; Krummenacher C
PLoS One; 2019; 14(2):e0212443. PubMed ID: 30759143
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of PR/SET domain 10 underlies natural killer cell dysfunction in hepatocellular carcinoma.
Han J; Ke C; Jiang B; Zhou H; Xu H; Xie X
Clin Exp Immunol; 2021 Dec; 206(3):366-377. PubMed ID: 34562314
[TBL] [Abstract][Full Text] [Related]
11. CD155, an onco-immunologic molecule in human tumors.
Gao J; Zheng Q; Xin N; Wang W; Zhao C
Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595
[TBL] [Abstract][Full Text] [Related]
12. UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells.
Gong J; Fang L; Liu R; Wang Y; Xing J; Chen Y; Zhuang R; Zhang Y; Zhang C; Yang A; Zhang X; Jin B; Chen L
Eur J Immunol; 2014 Dec; 44(12):3758-67. PubMed ID: 25209846
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
14. [CD226, TIGIT and CD96 regulate NK cell function and participate in anti-tumor immunity].
Zhang H; Liu R; Zhang Y; Liu X; Chen L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Sep; 39(9):852-856. PubMed ID: 37732582
[TBL] [Abstract][Full Text] [Related]
15. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
16. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.
Blake SJ; Stannard K; Liu J; Allen S; Yong MC; Mittal D; Aguilera AR; Miles JJ; Lutzky VP; de Andrade LF; Martinet L; Colonna M; Takeda K; Kühnel F; Gurlevik E; Bernhardt G; Teng MW; Smyth MJ
Cancer Discov; 2016 Apr; 6(4):446-59. PubMed ID: 26787820
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles.
Wu M; Mei F; Liu W; Jiang J
Biomed Pharmacother; 2020 Jan; 121():109637. PubMed ID: 31810126
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the Characteristics of TIGIT-Expressing CD3
Zhang X; Lu X; Cheung AKL; Zhang Q; Liu Z; Li Z; Yuan L; Wang R; Liu Y; Tang B; Xia H; Wu H; Zhang T; Su B
Front Immunol; 2021; 12():602492. PubMed ID: 33717085
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of Tumor-Infiltrating CD49a
Sun H; Liu L; Huang Q; Liu H; Huang M; Wang J; Wen H; Lin R; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Cancer Immunol Res; 2019 Sep; 7(9):1535-1546. PubMed ID: 31311791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
